Türk Medline
ADR Yönetimi
ADR Yönetimi

ADENOID CYSTIC CARCINOMA; A SINGLE CENTER 15 YEARS EXPERIENCE AND LITERATURE REVIEW

CELAL ALANDAG, SEHER NAZLİ KAZAZ, BENGU COBANOGLU

Eurasian Journal of Medical Investigation - 2021;5(4):491-495

Department of Medical Oncology, Sivas Numune Hospital, Sivas, Turkey

 

Objectives: Adenoid cystic carcinoma (ACC) is a rare tumor that arises from the salivary glands. Since it is rare, there are no consensus recommendations on its treatment strategy. Surgery, radiotherapy (RT), and systemic treatments are options We aimed to evaluate the treatment outcomes and prognostic factors in ACC. Methods: In this retrospective study; 17 ACC patients were included who were diagnosed with between January 2005 and April 2020 in Karadeniz Technical University Faculty of Medicine. We analyzed the demographic data of these 17 patients, effects of inflammatory markers on overall survival (OS) and progression-free survival (PFS). Results: Ten women and seven men were included in this study. At the diagnosis, 6 patients were metastatic, 5 of them had received chemotherapy. There was no statistical difference in overall survival according to neutrophil/lymphocyte ratio (N/L) and platelet/lymphocyte (T/L) ratio. Conclusion: Primary surgery is the most effective treatment, If possible, metastasectomy should be performed. ACC is a chemotherapy-resistant disease, so chemotherapy should only be given to metastatic, symptomatic, and fıt patients. We did not detect the prognostic effect of T/L and N/L in a limited number of ACC samples.